SFI
COGT icon

Susquehanna Fundamental Investments’s Cogent Biosciences COGT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,601
Closed -$287K – 1541
2020
Q4 		$287K Buy
25,601
+8,751
+52% +$96.2K 0.01% 1271
2020
Q3 		$158K Buy
+16,850
New +$176K ﹤0.01% 1234

Other funds holding COGT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna Fundamental Investments's COGT Position: Q1 2021 in Review

Susquehanna Fundamental Investments sold out of Cogent Biosciences (COGT) in Q1 2021, closing a stake of 25,601 shares — an estimated $287K sold.

Susquehanna Fundamental Investments first reported a position in COGT in Q3 2020 and held it in 2 quarters. The position peaked at $287K in Q4 2020. 69 funds tracked by Wall St. Rank hold COGT as of Q1 2021.

  • Susquehanna Fundamental Investments reported no remaining Cogent Biosciences position as of Q1 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 25,601 Cogent Biosciences shares in Q1 2021, an estimated $287K.
  • Susquehanna Fundamental Investments first reported a position in Cogent Biosciences in Q3 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Cogent Biosciences position peaked at $287K in Q4 2020.
  • 69 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2021, filed 17 May 2021.